ValoreQ4, 25TTMSpese di vendita, generali e amministrative——Ricerca e sviluppo——Reddito operativo-433 K—Proventi non operativi, Totale——Oneri finanziari, al netto degli interessi capitalizzati——Proventi non operativi, esclusi gli oneri finanziari——Entrate/uscite straordinarie——Utile al lordo delle imposte-659.85 M—Quota di utile——Imposte1.86 M—Interessi di minoranza——Altri proventi/oneri al netto delle imposte——Utile netto al lordo delle attività cessate-661.71 M—Attività cessate——Utile netto-661.71 M—Regolazione della diluizione——Dividendi privilegiati——Utile netto diluito attribuibile agli azionisti ordinari-661.71 M—Utile base per azione (EPS base)——Utile diluito per azione (EPS diluito)-2.92—Numero medio di azioni ordinarie in circolazione226.53 M—Azioni diluite in circolazione226.53 M—EBITDA——EBIT——Costo del fatturato——Altri costi del venduto——Ammortamento e svalutazione (liquidità)400 K—
AtaiBeckley Inc
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.